Literature DB >> 21784383

Progression from concentric left ventricular hypertrophy and normal ejection fraction to left ventricular dysfunction.

Richard V Milani1, Mark H Drazner, Carl J Lavie, Daniel P Morin, Hector O Ventura.   

Abstract

Concentric left ventricular (LV) hypertrophy develops in response to a chronically increased LV afterload and is associated with increased cardiovascular events. Although the progression to systolic and diastolic heart failure is a known consequence of LV hypertrophy, few data are available on the frequency of deterioration to systolic dysfunction in patients with LV hypertrophy who originally had a normal LV ejection fraction. We evaluated the baseline and follow-up characteristics in 1,024 patients with concentric LV hypertrophy and a normal ejection fraction who had paired echocardiograms that were separated by ≥1 year. Systolic dysfunction occurred in 134 patients (13%) after a mean follow-up of 33 ± 24 months. The most common associated variable was interval myocardial infarction, which occurred in 43% of patients. Other risk factors for developing LV systolic dysfunction included QRS prolongation (>120 ms) and elevated follow-up arterial impedance defined as a value >4.0 mm Hg/ml/m(2). Patients with either a prolonged QRS interval or an elevated follow-up arterial impedance had twice the likelihood of developing LV systolic dysfunction, and, if both factors were present, there was a greater than fourfold increased risk of developing systolic dysfunction. Blood pressure measurements alone did not adequately reflect an elevated arterial impedance. In conclusion, 13% of patients with a normal ejection fraction and concentric LV hypertrophy progress to systolic dysfunction during approximately 3 years of follow-up. The risk factors for loss of function were interval myocardial infarction, prolonged QRS, and chronically elevated arterial impedance.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21784383     DOI: 10.1016/j.amjcard.2011.05.038

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  15 in total

Review 1.  Treatment strategies for the prevention of heart failure.

Authors:  Justin L Grodin; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 2.  Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload.

Authors:  Gabriele G Schiattarella; Joseph A Hill
Journal:  Circulation       Date:  2015-04-21       Impact factor: 29.690

3.  The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects.

Authors:  D B Ojji; L H Opie; S Lecour; L Lacerda; O M Adeyemi; K Sliwa
Journal:  J Hum Hypertens       Date:  2014-01-09       Impact factor: 3.012

4.  Target organ damage and control of cardiovascular risk factors in hypertensive patients. Evidence from the multicenter ESTher registry.

Authors:  R K Reibis; M Huber; M Karoff; W Kamke; R Kreutz; K Wegscheider; H Völler
Journal:  Herz       Date:  2015-01-30       Impact factor: 1.443

5.  The natural history of left ventricular geometry in the community: clinical correlates and prognostic significance of change in LV geometric pattern.

Authors:  Wolfgang Lieb; Philimon Gona; Martin G Larson; Jayashri Aragam; Michael R Zile; Susan Cheng; Emelia J Benjamin; Ramachandran S Vasan
Journal:  JACC Cardiovasc Imaging       Date:  2014-08-13

Review 6.  Hypertension as a risk factor for heart failure.

Authors:  Arun Kannan; Rajesh Janardhanan
Journal:  Curr Hypertens Rep       Date:  2014-07       Impact factor: 5.369

Review 7.  Myocardial remodeling in hypertension.

Authors:  W Nadruz
Journal:  J Hum Hypertens       Date:  2014-05-08       Impact factor: 3.012

8.  Biomarkers of chronic cardiac injury and hemodynamic stress identify a malignant phenotype of left ventricular hypertrophy in the general population.

Authors:  Ian J Neeland; Mark H Drazner; Jarett D Berry; Colby R Ayers; Christopher deFilippi; Stephen L Seliger; Vijay Nambi; Darren K McGuire; Torbjørn Omland; James A de Lemos
Journal:  J Am Coll Cardiol       Date:  2012-12-05       Impact factor: 24.094

9.  Gender-specific differences in left ventricular remodelling in obesity: insights from cardiovascular magnetic resonance imaging.

Authors:  Oliver J Rider; Adam Lewandowski; Richard Nethononda; Steffen E Petersen; Jane M Francis; Alex Pitcher; Cameron J Holloway; Sairia Dass; Rajarshi Banerjee; James P Byrne; Paul Leeson; Stefan Neubauer
Journal:  Eur Heart J       Date:  2012-10-10       Impact factor: 29.983

10.  Assessment of Left Ventricular Mass and Hypertrophy by Cardiovascular Magnetic Resonance Imaging in Pediatric Hypertension.

Authors:  Katarina Supe-Markovina; James C Nielsen; Muzammil Musani; Laurie E Panesar; Robert P Woroniecki
Journal:  J Clin Hypertens (Greenwich)       Date:  2016-03-14       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.